biOasis Technologies Ord Shs BIOAF

Primary Symbol: V.BTI.H

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Causing Implausible Speculation, With No Responsibilty

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Feb 22, 2023 2:46pm

105 Views

Post# 35299020

RE:RE:RE:RE:Causing Implausible Speculation, With No Responsibilty

"Maybe it's the ease with which Carina, as a private company, can be operated that helped inform DrDR that she'd rather work with xB3 if it's in "other" hands than with Bioasis and its mindlessly negative shareholders."

Rathjen has tried to get BTI in competent financial hands. She tried to move from the TSX-V, jd, and the seven simps to NASDAQ, Ladenberg, and Armistice Capital. She's been trying to move beyond Herceptin to give it a better horse. The new Lysosomal Storage, inflammation, neurodegeneration strategic focus is validated, in part, by Chiesi. She's added Cresence which is Phase II ready which the market wants right now as opposed to preclinical. Biodexa would have had a potential US$20 million finncial runway to hard human clinical data, etc.Rathjen has been trying to reset the history of falure that has been BTI's story and give it a chance.

Boomskid wrote: It's nonsense to say that DrDR has ridden her horse to victory with Carina. It's the type of statement you'd expect from an investing neophyte like poof.

Carina is a private company backed by venture capitalists (VCs). It's the VCs who are driving Carina, funding it, and have positioned DrDR as Carina's front end.

Private capital is seeing to it that Carina continues to function unless its IP shows diminishing value. DrDR's job is to implement the plan, approved and funded by the VCs, to prove Carina's IP. It's the VCs who decide the life or death of Carina.

Maybe it's the ease with which Carina, as a private company, can be operated that helped inform DrDR that she'd rather work with xB3 if it's in "other" hands than with Bioasis and its mindlessly negative shareholders.

jd